New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.
Kevin Kaiserman, MD
Advertisement
Kevin Kaiserman, MD, is senior vice president and therapeutic area head for diabetes at MannKind Corporation.
Articles by Kevin Kaiserman, MD
Kevin Kaiserman, MD, discusses how FDA approval of Afrezza gives children aged 6 years and older with diabetes a new mealtime insulin option.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA issues Warning Letter to SNOO Smart Sleeper maker over unauthorized sleep sacks, hospital bundle, and quality system failures
2
Chronicity, Symptom Variability, and Treatment Expectations in Pediatric Functional Constipation and IBS-C
3
Vosoritide data support planned FDA submission for hypochondroplasia
4
Setmelanotide shows interim phase 2 signals in Prader-Willi syndrome
5